Bedrijfsoverzicht
UroGen Pharma Ltd. is a biotechnology entity dedicated to the development and commercialization of therapeutic solutions specifically targeting urothelial and specialty cancers. Within the broader Healthcare sector and the specialized Biotechnology industry, the company focuses on advancing novel technologies to address complex oncological conditions. The firm employs a workforce of 291 individuals and holds a market capitalization of $1.05 billion. Its annual revenue for the trailing twelve months stands at $109.79 million. These valuation metrics and revenue figures position UroGen Pharma as a mid-to-large-cap player within the biotechnology landscape, indicating significant capitalization relative to its revenue base. The company's substantial market cap suggests that the market places a high value on its proprietary pipeline, particularly its RTGel technology and its generic drug offerings. This scale implies that the organization has secured a level of investor confidence that supports continued R&D expenditures without immediate pressure for profitability.
Financiële gezondheid
The company reported total revenue of $109.79 million, a net income of -$153,494,000, and an EBITDA of -$124,556,000 for the trailing twelve months. The substantial gap between positive revenue and significantly negative net income reveals a cost structure where operating expenses, likely driven by research and development and commercialization efforts, far exceed gross profit margins. Free cash flow stands at -$99,423,000, which indicates that the company is currently burning cash rather than generating liquidity, limiting its immediate financial flexibility to fund operations without external capital injections. Gross margin is reported at 88.7%, reflecting high efficiency in the cost of goods sold, whereas the operating margin is -50.5% and the profit margin is -139.8%, signaling intense operational costs and a lack of bottom-line profitability. Total cash on hand is $120.46 million, compared to total debt of $130.09 million, resulting in a net cash position that is slightly negative, though the debt-to-equity ratio is listed as N/A due to accounting conventions for loss-making entities. The current ratio is 4.01, which indicates a robust short-term liquidity position with current assets significantly exceeding current liabilities. Return on Equity is N/A, while Return on Assets is -32.1%, metrics that reveal management is currently utilizing the company's asset base to generate losses rather than positive returns.
Waarderingsbeoordeling
The trailing twelve months P/E ratio is N/A, while the forward P/E is 20.74, implying that the market expects significant earnings improvement to bridge the current gap between negative historical earnings and positive future projections. The price-to-book ratio is -9.89, a negative figure that indicates the company's market capitalization is valued below its book value, often seen in biotechnology firms where future pipeline potential outweighs current tangible asset value. The price-to-sales ratio stands at 9.56, and the EV/EBITDA is -8.51, suggesting that investors are willing to pay a premium of nearly ten times sales despite the lack of current earnings, a common valuation metric in growth-oriented sectors. The stock's 52-week high is $30.00 and the 52-week low is $3.42, meaning the current price sits well below the recent peak, reflecting significant volatility over the past year. The beta value is 1.44, which signifies that the stock's price volatility is substantially higher than the broader market, exposing holders to greater swings in share price relative to market movements.
Growth & Income
Revenue growth year-over-year is 54.0%, while earnings growth year-over-year is N/A, indicating that the company is scaling its top line rapidly but has not yet achieved consistent earnings growth due to ongoing losses. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings are theoretically reinvested into research, development, and commercialization rather than distributed to shareholders. The absence of a dividend payout aligns with the company's stage of development, where capital is prioritized for expanding the urothelial cancer solution portfolio rather than returning value to investors. Overall, the company presents a growth profile characterized by aggressive revenue expansion and zero income distribution, relying on the successful commercialization of its proprietary hydrogel technology and generic drug portfolio to eventually transition to profitability.